BioStack announced that it's launching a data infrastructure network to power the next era of medicine. It spans a global footprint across the U.S., India, Brazil, and Argentina with over 100 million de-identified patient records. By connecting fragmented clinical information, BioStack gives AI and biotech companies the high-quality data needed to train models that understand how disease unfolds, how treatments work, and what drives patient outcomes.

The company also announced $9.5 million in seed funding led by Peak XV, Afore Capital, DCVC, Emerson Collective, SV Angel, Verdict Capital, Streamlined Ventures, and Y Combinator. The round will support BioStack's continued expansion across the United States and international markets, development of its technology platform and growth of its engineering and research teams.

BioStack is building the data infrastructure for the next generation of healthcare and medical AI. The company connects fragmented clinical information across healthcare systems to create longitudinal patient records spanning notes, labs, imaging, medications, treatment and outcomes. BioStack de-identifies this information to create proprietary datasets that support healthcare research, biotechnology and the development and evaluation of medical AI.